Glutaminyl Cyclase Inhibitor 4

• CAT Number: I018082
• CAS Number: 2376329-36-9
• Molecular Formula: C₂₂H₃₃N₅O₃
• Molecular Weight: 415.53
• Purity: ≥95%
• IUPAC Name: 1-(3,4-dimethoxyphenyl)-3-[3-(5-methylimidazol-1-yl)propyl]-1-(1-methylpiperidin-4-yl)urea
• InChI: InChI=1S/C22H33N5O3/c1-17-15-23-16-26(17)11-5-10-24-22(28)27(18-8-12-25(2)13-9-18)19-6-7-20(29-3)21(14-19)30-4/h6-7,14-16,18H,5,8-13H2,1-4H3,(H,24,28)
• InChIKey: APMPRURNDCVMST-UHFFFAOYSA-N
• SMILES: CC1=CN=CN1CCCNC(=O)N(C2CCN(CC2)C)C3=CC(=C(C=C3)OC)OC

Glutaminyl Cyclase Inhibitor 4 (GCi4)（Cat No.:I018082）is a small molecule inhibitor that targets glutaminyl cyclase (QC), an enzyme involved in the synthesis of pyroglutamate, a modified amino acid. Pyroglutamate has been implicated in neurodegenerative diseases like Alzheimer’s, as it can accumulate in the brain and interfere with cognitive function. By inhibiting glutaminyl cyclase, GCi4 aims to reduce the formation of pyroglutamate and potentially slow the progression of such diseases. Preclinical studies suggest GCi4 holds promise in treating Alzheimer’s disease and other neurodegenerative conditions, although more research is needed to evaluate its efficacy and safety.

Reference

[1]. Hoang VH, et al. Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer’s Agents by Structure-Based Design. J Med Chem. 2019 Aug 27.